Frankfurt - Delayed Quote • EUR Galectin Therapeutics Inc. (PHPN.F) Follow 3.2200 0.0000 (0.00%) At close: April 26 at 9:41 PM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for PHPN.F 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: PHPN.F View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21% Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023 UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023 Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis Related Tickers CABA Cabaletta Bio, Inc. 11.01 -9.61% ATHE Alterity Therapeutics Limited 2.5100 +9.61% GERN Geron Corporation 3.7900 +6.46% MNMD Mind Medicine (MindMed) Inc. 8.52 0.00% RXRX Recursion Pharmaceuticals, Inc. 8.12 +3.57%
